16p ask now:
EBITDA is now guided to be at the higher end
of its �3.5 million to �4 million target for the full
year. This compares to a �300,000 loss a year
earlier and offers material evidence that the
group is turning a corner.
In
the trading update (6 July) management stated
that earnings before interest, tax, depreciation
and amortisation (EBITDA) was ahead of market
expectations in the first half
Upgrades could be on the way for
medical testing kit-maker EKF
Diagnostics (EKF:AIM) after a
difficult couple of years. Buy before the
market digests what are expected to be upbeat
half year results on 12 September
investments are worth $30m. But hard to sell them? Also 2 year case settled. Interesting for £9m mcap. 5P is possible short term I guess but HIGH RISK.